6-Ketoprogesterone

An oxidised progesterone metabolite and reference steroid that keeps a faint progesterone-like central depressant action while shedding progestational activity; only marginally a neurosteroid.

No controlled human safety data exist for 6-ketoprogesterone; it has not been developed as a medicine and is not intended for human consumption. The available pharmacology is limited to mid-twentieth-century animal work, in which the most prominent effect at higher doses was a progesterone-like depression of the central nervous system, alongside a weak anabolic (myotrophic) action and little androgenic or estrogenic activity. As a steroidal compound it should be presumed capable of endocrine effects, and its uncharacterised metabolism, absence of formal toxicology and lack of pharmacokinetic data mean it warrants handling only as a laboratory reference chemical rather than as a supplement or therapeutic agent.

The compound entered the literature in 1956, when Hagopian, Pincus and colleagues reported isolating 6-ketoprogesterone, together with an unidentified substance, from perfusates of human placentae; the work came from the laboratory of Gregory Pincus, better known for the development of the combined oral contraceptive.

Its pharmacology was surveyed shortly afterwards by Nakao and coworkers, whose 1958 paper in Endocrinologia Japonica catalogued the compound's biological actions and first noted its dissociation of progesterone-like central and anabolic effects from progestational activity. Through the 1960s and 1970s a British group led by Fotherby developed assays for the urinary 6-oxygenated metabolites of progesterone (a class that includes 6-ketoprogesterone) and quantified their striking rise in pregnancy, work that fed arguments about feedback control of placental steroidogenesis.

Parallel analytical chemistry, notably Langenbach and Knoche's 1968 study, established that the C6 ketone forms readily by alkaline oxidation of progesterone and can distort progesterone measurement. In the 1980s the microsomal and adrenal oxidation pathways were dissected by Tan and colleagues, and the enzymology was refined in 1988 by Swinney and coworkers using purified cytochrome P-450g. More recent work has used 6-ketoprogesterone as a substrate probe in fungal biotransformation, for example in Aspergillus tamarii, where its C6 and D-ring functionality steers the course of microbial steroid conversion.

Within endocrinology 6-ketoprogesterone is an obscure but genuinely historical molecule: a footnote-level metabolite that nonetheless recurs across seven decades of steroid biochemistry, from placental perfusion experiments to cytochrome P450 kinetics. It has no clinical role and no meaningful presence in the nootropic or performance-enhancement community, and it is not sold as a dietary supplement; commercially it circulates almost entirely as a certified reference standard, catalogued under names such as Progesterone Impurity 17. A frequent point of confusion is its near-namesake 6-oxoandrostenedione (marketed as 6-OXO), a C19 androstenedione derivative once promoted as an over-the-counter aromatase inhibitor; that compound is chemically and pharmacologically distinct from the C21 pregnane described here, and the two should not be conflated.